The first approved COVID-19 drug is far from 'amazing'
Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and
Also in healthcare news: Gilead's set to make billions on a drug that's far from "amazing", AstraZeneca and Johnson & Johnson have restarted vaccine trials in the US, and universal masking could save 130,000.
Gilead is set to sell billions of dollars of a coronavirus drug that's far from 'amazing' after the US approved remdesivir to treat COVID-19
GileadSciences is poised to sell billions of dollars worth of the first COVID-19 treatment approved by US regulators, despite mixed evidence on whether or not the drug actually works.
- A trial conducted earlier this year found hospitalized COVID-19 patients taking
remdesivirrecovered modestly faster than those on getting a placebo. The study did not find that the drug reduced deaths in a statistically meaningful way.
- Despite the uncertainty on its efficacy, Wall Street analysts expect the drug to bring in more than $4 billion in revenue over 2020 and 2021.
AstraZeneca and Johnson & Johnson get FDA green light to resume coronavirus vaccine trials in the US after participants got sick
- Two major coronavirus
vaccinetrials — one by AstraZeneca and the University of Oxford, the other by Johnson & Johnson — will resume coronavirus vaccine trials in the US, the companies announced Friday.
- AstraZeneca's late-stage trial had paused September 6 after the company reported "suspected serious adverse reaction" in a UK-based participant.
- Johnson & Johnson halted trials on October 12 after a participant developed an unexplained illness.
- The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September, and in Japan earlier this month.
Universal mask-wearing could save 130,000 US lives before March, mitigating the worst of this 3rd coronavirus surge
- The US's total coronavirus deaths could surpass 511,000 by the end of February, according to a new University of Washington model.
- Nearly 130,000 of those lives could be saved if 95% of the country wore masks, the model found.
- Mask-wearing, the researchers wrote, could delay the need for lockdowns and mitigate the worst of the fall-winter surge.
More stories we're reading:
- WATCH: Horseshoe crab blood could help scientists create a coronavirus vaccine. Here's why the liquid is so expensive. (Business Insider)
- An inside look at the FDA's efforts to push back at Trump's rush to a vaccine (Vanity Fair)
- Blood plasma didn't show benefit in COVID-19 patients, according to a new study (Stat News)
- Merck scientists wanted to get started on vaccine in February, but were overruled by senior execs (The Wall Street Journal)
- How Adtech is helping to optimize revenue streams to monetization content for media & advertising during this age of online boom post COVID-19
- Russia to produce Sputnik V Covid vaccine in India
- Malaria No More India and Times Bridge launch a Google Assistant feature that will answer people’s queries on malaria
- Burger King India is all set to float its ₹810 crore IPO next week — Here are the details
- Bitcoin’s record run over seven weeks makes a sharp U-turn but experts call it a healthy correction